Detalhe da pesquisa
1.
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Drug Resist Updat
; 60: 100806, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121337
2.
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Med Res Rev
; 42(1): 112-155, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928670
3.
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Br J Cancer
; 123(5): 752-761, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32541873
4.
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Cancer Drug Resist
; 6(4): 709-728, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38239393
5.
Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
Cancers (Basel)
; 14(24)2022 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551613
6.
The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Front Immunol
; 13: 1001161, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268020
7.
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy.
Front Oncol
; 11: 697967, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568028
8.
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Front Immunol
; 12: 737311, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34557197